FI20205255A1 - Gastrin-17-test för undersökning och riskbedömning av dyspepsi och refluxsymtom, och atrofisk gastritis, med tillhörande risker - Google Patents

Gastrin-17-test för undersökning och riskbedömning av dyspepsi och refluxsymtom, och atrofisk gastritis, med tillhörande risker Download PDF

Info

Publication number
FI20205255A1
FI20205255A1 FI20205255A FI20205255A FI20205255A1 FI 20205255 A1 FI20205255 A1 FI 20205255A1 FI 20205255 A FI20205255 A FI 20205255A FI 20205255 A FI20205255 A FI 20205255A FI 20205255 A1 FI20205255 A1 FI 20205255A1
Authority
FI
Finland
Prior art keywords
gastrin
pylori
atrophic gastritis
risk
antrum
Prior art date
Application number
FI20205255A
Other languages
English (en)
Finnish (fi)
Inventor
Osmo Suovaniemi
Original Assignee
Biohit Oyj
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biohit Oyj filed Critical Biohit Oyj
Priority to FI20205255A priority Critical patent/FI20205255A1/sv
Priority to PCT/FI2021/050176 priority patent/WO2021181008A1/en
Publication of FI20205255A1 publication Critical patent/FI20205255A1/sv

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/062—Gastritis or peptic ulcer disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FI20205255A 2020-03-11 2020-03-11 Gastrin-17-test för undersökning och riskbedömning av dyspepsi och refluxsymtom, och atrofisk gastritis, med tillhörande risker FI20205255A1 (sv)

Priority Applications (2)

Application Number Priority Date Filing Date Title
FI20205255A FI20205255A1 (sv) 2020-03-11 2020-03-11 Gastrin-17-test för undersökning och riskbedömning av dyspepsi och refluxsymtom, och atrofisk gastritis, med tillhörande risker
PCT/FI2021/050176 WO2021181008A1 (en) 2020-03-11 2021-03-11 Gastrin-17 test for screening and risk assesment of dyspeptic and reflux symptoms, and atrophic gastritis, with related risks

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20205255A FI20205255A1 (sv) 2020-03-11 2020-03-11 Gastrin-17-test för undersökning och riskbedömning av dyspepsi och refluxsymtom, och atrofisk gastritis, med tillhörande risker

Publications (1)

Publication Number Publication Date
FI20205255A1 true FI20205255A1 (sv) 2021-09-12

Family

ID=75143669

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20205255A FI20205255A1 (sv) 2020-03-11 2020-03-11 Gastrin-17-test för undersökning och riskbedömning av dyspepsi och refluxsymtom, och atrofisk gastritis, med tillhörande risker

Country Status (2)

Country Link
FI (1) FI20205255A1 (sv)
WO (1) WO2021181008A1 (sv)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4139840B4 (de) * 1990-12-04 2005-06-02 Quidel Corp., San Diego Antigen-Zubereitung zum Nachweis von H. pylori
FI97304C (sv) 1994-11-16 1996-11-25 Locus Genex Oy Förfarande för screening av magkancerrisk
JP2011501177A (ja) 2007-10-26 2011-01-06 ビオヒット・ユルキネン・オサケユキテュア 自己免疫疾患および萎縮性胃炎と関連する胃癌を診断するための方法および製品
CN105242045A (zh) * 2014-06-13 2016-01-13 拜奥希特公司 胃泌素-17作为具有增加的数种相关后发病风险的萎缩性胃炎的生物标志物的用途

Also Published As

Publication number Publication date
WO2021181008A1 (en) 2021-09-16

Similar Documents

Publication Publication Date Title
Pathirana et al. Faecal calprotectin
Crusell et al. Gestational diabetes is associated with change in the gut microbiota composition in third trimester of pregnancy and postpartum
Meynaar et al. In critically ill patients, serum procalcitonin is more useful in differentiating between sepsis and SIRS than CRP, Il-6, or LBP
Kelly et al. Endomicroscopic and transcriptomic analysis of impaired barrier function and malabsorption in environmental enteropathy
US10295536B2 (en) Fecal lactoferrin as a biomarker for determining disease severity and for treating infection in patients with Clostridium difficile disease
JP5828849B2 (ja) 無症候性患者における全身性炎症反応症候群およびセプシスの早期診断および予測に基づくｉｌ−６の検出
Neujahr et al. Bile acid aspiration associated with lung chemical profile linked to other biomarkers of injury after lung transplantation
RU2635516C2 (ru) Способы и устройство для обнаружения глютеновой чувствительности и ее дифференцирования с целиакией
JP2015222271A (ja) 自己免疫疾患および萎縮性胃炎と関連する胃癌を診断するための方法および製品
Ministro et al. Fecal biomarkers in inflammatory bowel disease: how, when and why?
US20210108250A1 (en) Methods and devices for accurate diagnosis of infections
Gaddam et al. Circulating levels of hydrogen sulfide and substance P in patients with sepsis
Delefortrie et al. Comparison of the Liaison® Calprotectin kit with a well established point of care test (Quantum Blue—Bühlmann-Alere®) in terms of analytical performances and ability to detect relapses amongst a Crohn population in follow-up
Benito et al. Lack of value of midregional pro-adrenomedullin and C-terminal pro-endothelin-1 for prediction of severe bacterial infections in infants with fever without a source
US10295535B2 (en) Clostridium difficile dehydrogenase and toxin as a biomarker for monitoring infection in patients with clostridium difficile disease and differentiating carrier state from active disease
US20180171389A1 (en) Method of treating crohn's disease
Ngai et al. Intestinal injury in Ugandan children hospitalized with malaria
WO2015189480A1 (en) Use of gastrin-17 as biomarker for atrophic gastritis with increased risk of several related sequels
US9506923B2 (en) Method of diagnosing surgical site infections
FI20205255A1 (sv) Gastrin-17-test för undersökning och riskbedömning av dyspepsi och refluxsymtom, och atrofisk gastritis, med tillhörande risker
WO2016072464A1 (ja) デオキシハイプシン・シンターゼ遺伝子を指標として用いる動脈硬化及びがんの検出方法
WO2023183657A1 (en) Multiplexed screening assays and methods of using thereof
WO2021024856A1 (ja) 間質性肺炎のタンパク質診断バイオマーカー
Kapel et al. Fecal Calprotectin for the diagnosis and management of inflammatory bowel diseases
Sobczak et al. Post-Traumatic Stress Response and Appendicitis in Children—Clinical Usefulness of Selected Biomarkers